Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
10,994,020
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
100,618
-
Shares change
-
-53,225
-
Total reported value, excl. options
-
$130,801
-
Value change
-
-$133,237
-
Number of buys
-
7
-
Number of sells
-
-5
-
Price
-
$1.30
Significant Holders of Phio Pharmaceuticals Corp. - Common Stock, par value $0.0001 per share (PHIO) as of Q1 2025
13 filings reported holding PHIO - Phio Pharmaceuticals Corp. - Common Stock, par value $0.0001 per share as of Q1 2025.
Phio Pharmaceuticals Corp. - Common Stock, par value $0.0001 per share (PHIO) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 100,618 shares
of 10,994,020 outstanding shares and own 0.92% of the company stock.
Largest 10 shareholders include GEODE CAPITAL MANAGEMENT, LLC (41,586 shares), Cetera Investment Advisers (38,500 shares), XTX Topco Ltd (10,800 shares), MORGAN STANLEY (6,000 shares), Tower Research Capital LLC (TRC) (2,501 shares), SBI Securities Co., Ltd. (968 shares), ASSETMARK, INC (110 shares), UBS Group AG (103 shares), BANK OF AMERICA CORP /DE/ (41 shares), and Activest Wealth Management (9 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.